SCHEMBL310818

SCHEMBL310818

O=C1OC(=O)c2nccnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP2 O95551 1/20 0.40
NSD2 O96028 1/20 0.40
ABL1 P00519 1/20 0.40
PLCG1 P19174 1/20 0.40
CES1 P23141 1/20 0.40
PAX8 Q06710 1/20 0.40
RIN1 Q13671 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.36
S100A4 P26447 3/20 0.36
CDC25B P30305 3/20 0.36
PTPRC P08575 2/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13994697 0.77 ALOX15 (0.33) TDP1ALOX15
SCHEMBL311088 0.75 TDP2 (0.58) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL30694966 0.75 TDP2 (0.58) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL361673 0.72 KDM4E (0.37) TDP1KDM4E
SCHEMBL4709728 0.71 ALDH1A1 (0.36) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL4076284 0.70 NOS2 (0.38) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL17159951 0.69 ALDH1A1 (0.55) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL2936414 0.67 TDP1 (0.42) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL14380284 0.67 ALDH1A1 (0.36) ALDH1A1TDP1MEN1KMT2ATDP2
SCHEMBL7719621 0.65 S100A4 (0.54) ALDH1A1TDP1MEN1KMT2ATDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12620625-B2 Electrolyte solution for lithium-ion battery and lithium-ion battery BYD COMPANY LIMITED (CN) 2026-05-05 US claimed
US-20260018671-A1 SECONDARY BATTERY AND ELECTRONIC DEVICE NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2026-01-15 US claimed
EP-4613796-A1 STAR-SHAPED POLYMERS Evonik Operations GmbH (DE) 2025-09-10 EP claimed
CN-119757618-A Detection method of eszopiclone intermediate YZ1 related substances 江苏天士力帝益药业有限公司 2025-04-04 CN claimed
WO-2024192754-A1 SECONDARY BATTERY AND ELECTRONIC DEVICE 宁德新能源科技有限公司 2024-09-26 WO claimed
CN-117820811-B High-strength high-toughness easily-degradable epoxy resin composition, preparation method and application 中国科学院宁波材料技术与工程研究所 2024-06-18 CN claimed
CN-118027608-A Controllably degradable epoxy resin-based composite insulating material and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2024-05-14 CN claimed
CN-117903711-A Blue insulating tape applied to lithium battery and manufacturing method thereof 江西欣美新材料科技有限公司 2024-04-19 CN claimed
CN-117866200-A Polybenzoxazole precursor, process for producing the same, and photosensitive resin composition 上海交通大学 2024-04-12 CN claimed
CN-117820811-A High-strength high-toughness easily-degradable epoxy resin composition, preparation method and application 中国科学院宁波材料技术与工程研究所 2024-04-05 CN claimed
EP-2423215-A1 PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF Sanlugen Pharmatech Ltd. (CN) 2012-02-29 EP claimed
CN-102115485-A Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof SANLUGEN PHARMATECH 2011-07-06 CN claimed
CN-101525361-B Prodrug based on gemcitabine structure as well as synthesizing method and application thereof JINAN SHENGLUJIN PHARMACEUTICAL TECHNOLOGY DEV CO LTD 2010-11-17 CN claimed
US-7786304-B2 Process for the preparation of eszopiclone CENTAUR PHARMACEUTICAL PVT. LTD. (IN) 2010-08-31 US claimed
CN-101525361-A Prodrug based on gemcitabine structure as well as synthesizing method and application thereof SANLUGEN PHARMATECH DEV CO LTD 2009-09-09 CN claimed
EP-1725604-B1 CARBOXYLIC ACID COMPOUNDS COMPRISING ESTER BONDS AND POLYAMIDES PRODUCED THEREFROM LANXESS DEUTSCHLAND GMBH (DE) 2009-04-29 EP claimed
US-20080146800-A1 Process for the preparation of eszopiclone CENTAUR PHARMACEUTICAL PVT. LTD. (IN) 2008-06-19 US claimed
US-5532328-A Process for the preparation of a polymer DSM N.V. (NL) 1996-07-02 US claimed
EP-0633903-A1 PROCESS FOR THE PREPARATION OF A POLYMER FROM A HETEROCYCLIC MONOMER DSM N.V. (NL) 1995-01-18 EP claimed
WO-1994017120-A1 PROCESS FOR THE PREPARATION OF A POLYMER FROM A HETEROCYCLIC MONOMER DSM N.V. (NL) 1994-08-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146800-A1 Process for the preparation of eszopiclone CYP3A5, CYP3A7, CYP51A1 ALDH1A1 1055/4885TDP1 4701/4885MEN1 4427/4885
US-20260018671-A1 SECONDARY BATTERY AND ELECTRONIC DEVICE CACNA2D3, VMP1, CACNA2D2 ALDH1A1 3909/4885TDP1 2793/4885MEN1 1649/4885
US-12620625-B2 Electrolyte solution for lithium-ion battery and lithium-ion battery SLC9A1, HCN4, HCN1 ALDH1A1 1408/4885TDP1 2628/4885MEN1 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.